Viewing nowEzatine Tablets 20 mg (Memantine Hydrochloride)
Memantine Hydrochloride 20mg
Tablet · Prescription medication
AlboGen Korea Co., Ltd.

MFDS item code 202500223 · Approved 2025.02.04 · Insurance code 652607400
Treatment of moderate to severe Alzheimer's disease
This medication is used for the treatment of moderate to severe Alzheimer's disease.
Treatment must be initiated by a physician experienced in the diagnosis and treatment of Alzheimer’s dementia, and only if a caregiver can regularly check that the patient is taking the medication. The diagnosis should be made according to currently accepted guidelines. The clinical benefit of this medication and the patient’s tolerability of treatment should be regularly reassessed. This medication is administered orally once daily, at the same time each day. If necessary, it may be administered twice daily. It may be taken with or without food. 1. Adults Dose titration: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows to reach the maintenance dose. Week 1 (Days 1–7): Administer 5mg once daily for 7 days. Week 2 (Days 8–14): Administer 10mg once daily for 7 days. Week 3 (Days 15–21): Administer 15mg once daily for 7 days. From Week 4 onward, administer 20mg once daily. Maintenance dose: The recommended maintenance dose is 20mg once daily. 2. Older adults Based on clinical data, the recommended dose for older patients aged 65 years and over is 20mg once daily. 3. Patients with renal impairment No dose adjustment is required in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance: 30-49 mL/min), the daily dose should be reduced to 10mg. If the medication is well tolerated after at least 7 days of treatment, the dose may be increased to 20mg once daily according to the standard dose-titration schedule. In patients with severe renal impairment (creatinine clearance: 5-29 mL/min), the daily dose should be reduced to 10mg. 4. Patients with hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since no data are available on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medication.
This medication should not be used by patients with hypersensitivity to its ingredients or severe liver or kidney dysfunction. It should be used cautiously in patients with epilepsy or those with a history of seizures, or in patients who are at high risk of developing epilepsy. Additionally, co-administration with NMDA antagonists such as amantadine, ketamine, or dextromethorphan may increase central nervous system side effects, so it is better to avoid such combinations. Patients should be monitored carefully in situations where urinary pH may increase, such as dietary changes or certain urinary tract infections. Caution is advised for patients with myocardial infarction, congestive heart failure, or uncontrolled hypertension, as the safety of this medication has not been fully established in these populations. While taking this medication, side effects such as dizziness, headaches, constipation, drowsiness, and hypertension may occur, and if symptoms are severe, consultation with a healthcare professional is recommended. There may be interactions with other medications, particularly NMDA antagonists, levodopa, dopamine agonists, anticholinergic medications, barbiturates, antipsychotic medications, and skeletal muscle relaxants, so caution is necessary when taken together. Women who are pregnant or may become pregnant should carefully consider the risks to the fetus when using this medication. If breastfeeding, it is advisable to discontinue nursing when administering this medication due to the possibility of transmission through breast milk. For children and adolescents under 18 years of age, its safety and efficacy have not been established, so it is preferable not to use it in this population. In case of overdose, central nervous system symptoms and gastrointestinal symptoms may occur, and since there is no specific antidote, appropriate treatment based on symptoms is needed. This medication may reduce the patient's responsiveness, increasing the risk of accidents while driving or operating machinery, so caution is necessary. Finally, keep this medication out of reach of children, and do not transfer it to other containers as this is safer and better for maintaining quality.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a tightly closed container. It is also advisable to avoid extremely hot or cold places and to keep it at room temperature between 1 degree and 30 degrees Celsius.
Pink oval film-coated tablets
Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowMemantine Hydrochloride 20mg
Tablet · Prescription medication
AlboGen Korea Co., Ltd.
Memantine Hydrochloride 1g
Solution · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Ildong Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Youngjin Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Unimed Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Myongin Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.